Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 9 (5) |
| Completed vs Stopped Early | 3 / 4 (25.0%) |
| Median Closed Actual Enrollment | 108 participants |
| Physical Hospital Site Disclosure | 97.4% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 3 (2 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| MD Anderson Cancer Center | Houston, TX | 8 |
| Hospital Universitario 12 de Octubre | Madrid | 7 |
| Vanderbilt University Medical Center | Nashville, TN | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND St | Phase II/III | RECRUITING |
| NCT05967689 | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | Phase II | RECRUITING |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Phase II | RECRUITING |
| NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor | Phase III | RECRUITING |
| NCT05973773 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | Phase III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Taiho Oncology Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.